The BMT CTN 1506 is a randomized, phase III trial aimed to assess maintenance with gilteritinib vs. placebo after HSCT in patients with FLT3–ITD-mutated AML who achieved first CR (NCT02997202). Here, FLT3 is linked to acute myeloid leukemia.